GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Peptron Inc (XKRX:087010) » Definitions » Institutional Ownership

Peptron (XKRX:087010) Institutional Ownership : 8.24% (As of Jun. 22, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Peptron Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Peptron's institutional ownership is 8.24%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Peptron's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Peptron's Float Percentage Of Total Shares Outstanding is 0.00%.


Peptron Institutional Ownership Historical Data

The historical data trend for Peptron's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Peptron Institutional Ownership Chart

Peptron Historical Data

The historical data trend for Peptron can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 4.35 5.40 5.46 7.07 9.14 9.18 8.45 8.18 8.20 8.24

Peptron Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Peptron (XKRX:087010) Business Description

Traded in Other Exchanges
N/A
Address
37-24, Yuseong-daero 1628 beon-gil, Yuseong-gu, Daejeon, KOR, 305811
Peptron Inc is a biotechnology company engaged in developing fundamental technologies for peptide-based medicines. Its technology includes PeptrEX and SmartDepot. PeptrEX is an automatic system, enabling to synthesize simultaneously from a few to hundred types of peptides. SmartDepot is a proprietary ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of the drug. The group's research and development products include Luphere Depot for the treatment of prostate cancer and endometriosis, SR Exenatide PT302 AND SR EXENATIDE PT304 for the treatment of type II diabetes, SR Exenatide PT320 and 330 for the treatment of Parkinson's and Alzheimer's disease and SR Octreotide for the treatment of acromegaly and carcinoid tumor.

Peptron (XKRX:087010) Headlines

No Headlines